Skip to main
NGNE
NGNE logo

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene Inc is experiencing a positive outlook due to heightened confidence in its lead drug candidate, NGN-401, particularly regarding the management of HLH (Hemophagocytic Lymphohistiocytosis) reactions, which are critical for its clinical development. The company's advancements in monitoring HLH through ferritin levels suggest that they may effectively address safety concerns in future pivotal trials, thereby enhancing the probability of regulatory approval and successful market entry. Additionally, optimistic projections regarding trial enrollment and the ability to achieve statistically significant benefits for Rett syndrome patients contribute to a favorable sentiment surrounding Neurogene's long-term growth potential.

Bears say

Neurogene Inc faces significant financial risks due to the potential clinical failure of its key drug candidates, which could severely limit the company's ability to raise capital essential for its operations and growth. Additionally, investor sentiment regarding drug pricing, mergers and acquisitions, and overall sector valuations poses a further threat to the company's stock valuation. Moreover, there are numerous operational risks, including possible delays in advancing clinical candidates and generating favorable clinical data, particularly for NGN-401, which could exacerbate financial challenges and increase the risk of dilution for investors.

Neurogene Inc (NGNE) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Buy based on their latest research and market trends.

According to 6 analysts, Neurogene Inc (NGNE) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.